D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weisman, and M E Weinblatt
Ann Rheum Dis 2007 66: iii2-22.
erratum 66/iii2
This article mistakenly identifies all 3 anti-TNF agents (adalimumab, etanercept and infliximab) as having approval for the indication of juvenile idiopathic arthritis of the polyarticular type. Currently only etanercept holds this indication. The cited references to support the statement (refs 60-62) are all publications concerning etanercept.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
